Abstract
Synthesis of N-Substituted Benzamide Derivatives and their Evaluation as Antitumor Agents
Highlights
What’s more, histone deacetylases inhibitors (HDACIs) with different structures have been developed for cancer therapy, for instance, Chidamide has been approved by FDA to cure peripheral T-cell lymphoma (PTCL), Entinostat (MS-275) is in the clinical stage III to treat breast cancer, and so on
Biological efficacy of HDACIs is mainly attributed to the active structure which can coordinate with the zinc ion that exists in histone protein through hydrogen bond [8,9]
Most benzamide derivatives as HDACIs for cancer treatment mainly consist of three parts: zinc binding groups (ZBG), cap and a linker [10]
Summary
Cancer is traditionally seen as a genetic disease; its expansion is revealed to be associated with mutations resulting in activation of oncogenes or inactivation of tumor suppressor genes [1-3].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
